Safer Edits Smarter Cures
Gene Editing: How Do We Keep It Safe?
A new, exciting review led by Prof. Ayal Hendel and an international team of researchers (Germany, Italy, Spain, Denmark, UK, and Ireland) takes on one of the most pressing issues in gene editing: how to prevent unintended edits, known as off-target effects.
CRISPR-based therapies have shown remarkable potential, but questions around safety have slowed their path to the clinic. This paper offers more than just a summary of the risks- it lays out a clear, practical framework to address them.
🔍 Highlights from the work:
Concrete strategies for predicting and minimizing off-target activity
A comprehensive review of tools used to measure genomic safety
A push toward personalized editing, tailored to each patient’s genetic makeup
🧬 Why this matters:
As CRISPR moves closer to real-world therapies, precision is everything. This work sets the groundwork for safer, more reliable treatments, especially for complex diseases like cancer and inherited blood disorders.
Huge credit to Prof. Ayal Hendel, Nechama Kalter, and all partners for driving the field forward in such a meaningful way.
